Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company is headquartered in Seattle, Washington and currently employs 214 full-time employees. The company went IPO on 2015-04-15. The firm is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.

Industry: Pharmaceutical Preparations Peers: Akero Therapeutics, Inc. Veracyte Inc Catalyst Pharmaceuticals Inc Deciphera Pharmaceuticals, Inc. Kyntra Bio Inc Kymera Therapeutics Inc Rhythm Pharmaceuticals Inc SpringWorks Therapeutics, Inc. Zentalis Pharmaceuticals Inc